Other immune signatures of cancer immune status, namely PD-1, PD-L1, CTLA4, T cell immunoglobulin and mucin domain 3 (Tim3), IDO and IL-10, that potentially could be used as biomarkers of NACT response were analyzed in the pre-treatment biopsies. This evidence concerns the gene IL10 and cancer.